Scientific Advisory Board

NSI’s is supported by a hands-on Advisory Board of thought leaders from respected academic and corporate institutions along with various industry consultants.

Zahi Adel Fayad, PhD, FAHA, FACC, Professor in the departments of Radiology and
Medicine (Cardiology) at Mount Sinai School of Medicine in New York, is the Cardiovascular Chairman of NSID’s Scientific Advisory Board. He is founder and director of the Imaging Science Laboratories and also the director of the Eva and Morris Feld Cardiovascular Imaging Research Laboratory. He is on the board of trustees of the Society of Cardiovascular Magnetic Resonance, and has held Vice President and President positions at the Society of Atherosclerosis Imaging. He is on the editorial board of the Journal of Cardiovascular Magnetic Resonance, and was a member of the Annual Meeting Program Committee of the International Society of Magnetic Resonance in Medicine. He serves on the advisory board of several foundations, societies, and organizations, Merck Global Atherosclerosis Board, and is a fellow of the American Heart Association. Dr. Fayad has been the driving force behind NSI’s high-risk plaque initiative, has provided extensive research support and continues to direct access to key opinion leaders and strategic partners in the radiology and pharma field.

Chaitanya Divgi, MD is Penn Medicine’s Chief of Nuclear Medicine and Clinical Molecular Imaging. Coming from the Memorial Sloan-Kettering Cancer Center in New York, Divgi joined the Department of Radiology at Penn in May 2006. Dr. Divgi has a clinical research focus on radioimmunotherapy and targeted therapy. He is the author of more than 80 peer reviewed journal articles and enjoys an international reputation of excellence in his field. Dr. Divgi also serves as Professor of Radiology and Professor of Radiation Oncology at Penn. He is also a Professor at the
Wistar Institute and a Member of the Abramsom Cancer Center. Dr. Divgi’s high-level radiology and oncology experience together with his academic and corporate connections continue to be important contributors to NSID’s success.

William Mezzanotte, MD, FACCP, is Executive Director, Strategic Clinical Development at AstraZeneca Pharmaceuticals, focusing mostly on the company’s respiratory clinical trials and product development. He was involved in numerous FDA submissions and FDA meetings and was recently assigned US clinical oversight for new products in development in all therapeutic areas. Dr. Mezzanotte is a graduate of Villanova University and the University of Pennsylvania School of Medicine. He was a clinical and research fellow at the University of Colorado Health Sciences Center, and worked at the Denver Veterans Administration Medical Center and National Jewish Hospital for Respiratory Medicine. He is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine and has authored numerous articles. Dr. Mezzanotte is a member of the American College of Physicians, the American Thoracic Society, and the American College of Sleep Medicine. Dr. Mezzanotte has and will continue to help structure NSID’s strategic initiatives from his perspective as both a medical doctor and as a senior pharmaceutical executive with strong ties to the cardiovascular market.

James Mulshine, MD, Academic Provost at Rush University Medical Center and former Head of the Experimental Intervention Section, Cell and Cancer Biology at the National Cancer Institute, serves as the Oncology Chairman of NSID’s Scientific Advisory Board. Dr. Mulshine is a member of the American Society of Clinical Oncology, the American Association of Cancer Research, the International Association for the Study of Lung Cancer, and the American Federation of Clinical Research. He sits on the editorial boards of Lung Cancer, Clinical Cancer Research, and the International Journal of Oncology. He also serves as an editorial reviewer for Cancer, the New England Journal of Medicine, the British Journal of Cancer, and the European
Journal of Cancer, among others. 

Phil Vernon, Ph.D., spent nearly 15 years as a medical physicist in the United Kingdom before joining GE Medical Systems. He has held engineering and marketing roles within GE and prior to his retirement last fall, he was the Global Research Manager for PET and PET/CT. Phil's main responsibilities were focused on setting up and evaluating both internal and external research activities. External activities were primarily with university/medical school teams where GE funded research that was in line with GE's objectives, especially clinical trials to evaluate new technology. Internal programs were primarily focused on imaging technology. It was during his tenure that GE acquired Amersham's business, and so he became more closely involved with tracer development -- though his main roles were in strategic planning. Phil's role at GE Healthcare was to answer those questions. His primary role at NSI will be to help develop a meaningful relationship with GE's CT strategic planning group.

Harry Zegel, MD, FACR, is Chair of the Department of Radiology at Main Line Health System and Chief Radiologist at Lankenau Hospital. Previous positions include Chief of Service and Director of Abdominal Radiography, Department of Radiology, Allegheny University Hospitals, Medical College of Pennsylvania. Harry served as Vice Chairman, Department of Medical Imaging, Presbyterian Medical Center, Hospital of the University of Pennsylvania. He has also held positions at Riverside Hospital in Wilmington, the Philadelphia Heart Institute, St. Agnes Medical Center and Hospital, and Hahnemann University. Harry is widely published and has received numerous awards. Harry will be our resident practitioner, keeping us in close contact with the way our ultimate consumers view and are likely to use N1177-iv.

Contact Us

NanoScan Imaging, LLC
2250 Berks Road
Lansdale, PA 19446
P: 610-647-3231
info@nanoscanimaging.com
www.nanoscanimaging.com


Resources & Information

Product Applications:

Business Development:

Advisors: